Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This phase II trial investigates how well brentuximab vedotin and bendamustine work in
treating patients with follicular lymphoma that has come back (relapsed) or does not respond
to treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked
to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a
targeted way and delivers vedotin to kill them. Chemotherapy drugs, such as bendamustine,
work in different ways to stop the growth of cancer cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. This trial is being done to
determine if the combination of brentuximab vedotin plus bendamustine is safe and to
determine the effectiveness of the combination.
Phase:
Phase 2
Details
Lead Sponsor:
Joseph Tuscano
Collaborators:
National Cancer Institute (NCI) Seagen Inc. Seattle Genetics, Inc.